<SEC-DOCUMENT>0001493152-19-005751.txt : 20190423
<SEC-HEADER>0001493152-19-005751.hdr.sgml : 20190423
<ACCEPTANCE-DATETIME>20190423075146
ACCESSION NUMBER:		0001493152-19-005751
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20190423
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190423
DATE AS OF CHANGE:		20190423

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Microbot Medical Inc.
		CENTRAL INDEX KEY:			0000883975
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				943078125
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19871
		FILM NUMBER:		19760663

	BUSINESS ADDRESS:	
		STREET 1:		175 DERBY ST. 27/1
		STREET 2:		.
		CITY:			HINGHAM
		STATE:			MA
		ZIP:			02043
		BUSINESS PHONE:		908-938-5561

	MAIL ADDRESS:	
		STREET 1:		175 DERBY ST. 27/1
		STREET 2:		.
		CITY:			HINGHAM
		STATE:			MA
		ZIP:			02043

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	STEMCELLS INC
		DATE OF NAME CHANGE:	20000524

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CYTOTHERAPEUTICS INC/DE
		DATE OF NAME CHANGE:	19930328
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8-k.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 18pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>FORM
8-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CURRENT
REPORT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pursuant
to Section 13 or 15(d)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>of
the Securities Exchange Act of 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date
of Report (Date of earliest event reported): April 23, 2019</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>MICROBOT
MEDICAL INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Exact
name of registrant as specified in its charter)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 32%; font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 32%; font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>000-19871</B></FONT></TD>
    <TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 32%; font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>94-3078125</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(State
        or other jurisdiction</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>of
        incorporation)</B></FONT></P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Commission</B></FONT></P>
                                                                             <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>File Number)</B></FONT></P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(IRS
        Employer</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Identification
        No.)</B></FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>25
Recreation Park Drive, Unit 108</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Hingham,
Massachusetts 02043</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Address
of Principal Executive Offices) (Zip Code)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registrant&rsquo;s
telephone number, including area code: (781) 875-3605</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Former
Name or Former Address, if Changed Since Last Report)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
    communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>[&nbsp;&nbsp;]</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting
    material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">[&nbsp;&nbsp;]<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR
&sect;230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR &sect;240.12b-2).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
Growth Company [&nbsp;&nbsp;]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [&nbsp;&nbsp;]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; border-bottom: Black 4pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.75in; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
7.01</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Regulation
    FD Disclosure.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 23, 2019, Microbot Medical Inc.  issued a press release announcing that it has expanded its IP
portfolio as it received a Notice of Allowance from the Canadian Intellectual Property Office for Patent Application No. 2,850,279,
which pertains to a device for the prevention of shunt stenosis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information in this report (including Exhibit 99.1) is being furnished pursuant to Item 7.01 and shall not be deemed to be
&ldquo;filed&rdquo; for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to
the liabilities of that section. This report will not be deemed an admission as to the materiality of any information herein (including
Exhibit 99.1).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.75in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
    9.01.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Financial
    Statements and Exhibits.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>(d)
Exhibits</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="white-space: nowrap; width: 0.75in; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit<BR>

    Number</B></FONT></TD>
    <TD STYLE="width: 0.1in; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="white-space: nowrap; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><A HREF="ex99-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press release, dated April 23, 2019</FONT></A></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MICROBOT
    MEDICAL INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 45%; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Harel Gadot</I></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Harel
    Gadot</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer, President and Chairman</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
April 23, 2019</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin-top: 0; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex99-1_001.jpg" ALT="" STYLE="height: 70; width: 180"></FONT></P>

<P STYLE="margin-top: 0; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin-top: 0; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; margin-left: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Microbot
Medical Strengthens Global IP Portfolio with Canadian Notice of Allowance for a Patent Application for a Shunt Stenosis Prevention
System</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HINGHAM,
MA - April 23, 2019</B> &ndash; As it continues to receive an overwhelming positive response from global jurisdictions, Microbot
Medical Inc. (NASDAQ: MBOT) expands its IP portfolio as it receives a Notice of Allowance from the Canadian Intellectual Property
Office for Patent Application No. 2,850,279, which pertains to a device for the prevention of shunt stenosis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
this latest Notice of Allowance, the Company now has 32 issued/allowed patents and 19 patent applications pending worldwide.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;As
we continue to make progress on our primary clinical objectives, we have also excelled at expanding Microbot&rsquo;s innovative
IP portfolio, globally,&rdquo; commented Harel Gadot, CEO, President and Chairman. &ldquo;This latest allowance in Canada represents
another significant step toward achieving this goal and creating value that cements our positions as an emerging global leader
in micro-robotics.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
allowed patent application covers a system for reducing venous stenosis associated with the use of hemodialysis shunts. A clearing
device is inserted, and exerted, through a first bore, while dialyzed blood is being returned into the blood vessel through a
second bore. The clearing device may be a passive device moved down the blood vessel by the blood flow or an autonomous crawling
device, such as the Company&rsquo;s TipCat&trade; device, which is based on a series of sequentially inflatable chambers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Microbot Medical, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot&trade;,
which was founded in 2010 and commenced operations in 2011, became a NASDAQ listed company on November 28, 2016. The Company specializes
in transformational micro-robotic medical technologies leveraging the natural and artificial lumens within the human body. Microbot&rsquo;s
current technological platforms, ViRob&trade;, TipCAT&trade; and CardioSert&trade;, are comprised of three highly advanced technologies,
from which the Company is currently developing its first product candidate: The Self-Cleaning Shunt, or SCS&trade;, for the treatment
of hydrocephalus and Normal Pressure Hydrocephalus, or NPH. The Company also is focused on the development of a Multi Generation
Pipeline Portfolio (MGPP) utilizing all technologies. Further information about Microbot Medical is available at http://www.microbotmedical.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 70; width: 180">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ViRob&trade; technology is a revolutionary autonomous crawling micro-robot which can be controlled remotely or within the body.
Its miniature dimensions allow it to navigate and crawl in different spaces within the human body, including blood vessels, the
digestive tract and the respiratory system. Its unique structure gives it the ability to move in tight spaces and curved passages
as well as the ability to remain within the human body for prolonged time. To learn more about ViRob&trade; please visit http://www.microbotmedical.com/technology/virob/.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TipCAT&trade;
is a transformational self-propelled, flexible, and semi-disposable locomotive device providing see &amp; treat capabilities within
tubular lumens in the human body such as the colon, blood vessels, and the urinary tract. Its locomotion mechanism is perfectly
suitable to navigate and crawl through natural &amp; artificial tubular lumens, applying the minimal necessary pressure to achieve
the adequate friction required for gentle, fast, and safe advancement within the human body. To learn more about TipCAT&trade;,
visit http://www.microbotmedical.com/technology/tipcat/.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CardioSert&trade;
technology contemplates a unique combination of a guidewire and microcatheter, technologies that are broadly used for endoluminal
surgery. The CardioSert&trade; technology features unique steering and stiffness control capabilities, and it was originally developed
to support interventional cardiologists in crossing the most complex lesions called chronic total occlusion (CTO) during percutaneous
coronary intervention (PCI) procedures and has the potential to be used in other spaces and applications, such as peripheral intervention,
neurosurgery and urology. CardioSert&trade; was part of a technological incubator supported by the Israel Innovation Authorities
(formerly known as the Office of the Chief Scientist, or OCS), and its device has successfully completed pre-clinical testing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Safe
Harbor</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statements
pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential
opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs,
goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical
fact (including, but not limited to statements that contain words such as &ldquo;will,&rdquo; &ldquo;believes,&rdquo; &ldquo;plans,&rdquo;
&ldquo;anticipates,&rdquo; &ldquo;expects&rdquo; and &ldquo;estimates&rdquo;) should also be considered to be forward-looking
statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development
and/or commercialization of potential products, the outcome of its studies to evaluate the SCS and other existing and future technologies,
uncertainty in the results of pre-clinical and clinical trials or regulatory approvals, need and ability to obtain future capital,
maintenance of intellectual property rights, and the outcomes with respect to any litigation the Company is involved in from time
to time (including the success of any appeals). Actual results may differ materially from the results anticipated in these forward-looking
statements and as such should be evaluated together with the many uncertainties that affect the businesses of Microbot Medical
Inc. particularly those mentioned in the cautionary statements found in Microbot Medical Inc.&rsquo;s filings with the Securities
and Exchange Commission. Microbot Medical disclaims any intent or obligation to update these forward-looking statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investor
Contact: </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
Polyviou</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #000000">EVC
Group</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; color: blue"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #000000"><U>mpolyviou@evcgroup.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">732-933-2754</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !7 .$# 2(  A$! Q$!_\0
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M$D$$#M715Y)X#_Y'"/\ Z]W_ )BO6Z "BBB@ HHHH ***S-6UVRT8QBZ9@9
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)44 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_001.jpg
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !7 .$# 2(  A$! Q$!_\0
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M@5QWAOPW-XDO)@9F@LX" [I]YV]!6YKG@!-.T^2[T^YFD\E=SQ2G.X=\'UH
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+*M444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
